BACKGROUND: The Joint Commission requires that all medical inpatients be assessed for venous thromboembolism (VTE) risk, but available risk stratification tools have never been validated. METHODS: We conducted a retrospective cohort study of patients age≥18 years, admitted to 374 US hospitals in 2004-2005, with a primary diagnosis of pneumonia, heart failure, chronic obstructive pulmonary disease (COPD), stroke, and urinary tract infection, and length of stay ≥3 days. Subjects were randomly assigned (80/20) to a derivation or validation set. We then assessed VTE (International Classification of Diseases, Ninth Revision [ICD-9] code plus diagnostic test plus treatment), patient demographics, 21 potential risk factors, and other comorbidities. We created a VTE risk stratification tool using multivariable regression modeling and applied it to the validation sample. RESULTS:Of 242,738 patients, 612 (0.25%) patients fulfilled our criteria for VTE during hospitalization, and an additional 440 (0.18%) were readmitted for VTE within 30 days (overall incidence of 0.43%). In the multivariable model, age, sex, and 10 additional risk factors were associated with VTE. The strongest risk factors were inherited thrombophilia (OR 4.00), length of stay ≥6 days (OR 3.22), inflammatory bowel disease (OR 3.11), central venous catheter (OR 1.87), and cancer. In the validation set, the model had a c-statistic of 0.75 (95% CI 0.71, 0.78). Deciles of predicted risk ranged from 0.11% to 1.46% with observed risk over the same deciles from 0.17% to 1.81%. CONCLUSIONS: The risk of symptomatic VTE in general medical patients is low. A risk factor model can identify those at sufficient risk to warrant pharmacologic prophylaxis.
RCT Entities:
BACKGROUND: The Joint Commission requires that all medical inpatients be assessed for venous thromboembolism (VTE) risk, but available risk stratification tools have never been validated. METHODS: We conducted a retrospective cohort study of patients age ≥18 years, admitted to 374 US hospitals in 2004-2005, with a primary diagnosis of pneumonia, heart failure, chronic obstructive pulmonary disease (COPD), stroke, and urinary tract infection, and length of stay ≥3 days. Subjects were randomly assigned (80/20) to a derivation or validation set. We then assessed VTE (International Classification of Diseases, Ninth Revision [ICD-9] code plus diagnostic test plus treatment), patient demographics, 21 potential risk factors, and other comorbidities. We created a VTE risk stratification tool using multivariable regression modeling and applied it to the validation sample. RESULTS: Of 242,738 patients, 612 (0.25%) patients fulfilled our criteria for VTE during hospitalization, and an additional 440 (0.18%) were readmitted for VTE within 30 days (overall incidence of 0.43%). In the multivariable model, age, sex, and 10 additional risk factors were associated with VTE. The strongest risk factors were inherited thrombophilia (OR 4.00), length of stay ≥6 days (OR 3.22), inflammatory bowel disease (OR 3.11), central venous catheter (OR 1.87), and cancer. In the validation set, the model had a c-statistic of 0.75 (95% CI 0.71, 0.78). Deciles of predicted risk ranged from 0.11% to 1.46% with observed risk over the same deciles from 0.17% to 1.81%. CONCLUSIONS: The risk of symptomatic VTE in general medical patients is low. A risk factor model can identify those at sufficient risk to warrant pharmacologic prophylaxis.
Authors: Fan Ye; Carolyn Stalvey; Matheen A Khuddus; David E Winchester; Hale Z Toklu; Joseph J Mazza; Steven H Yale Journal: J Thromb Thrombolysis Date: 2017-07 Impact factor: 2.300
Authors: Wei Huang; Frederick A Anderson; Frederick A Spencer; Alexander Gallus; Robert J Goldberg Journal: J Thromb Thrombolysis Date: 2013-01 Impact factor: 2.300
Authors: Andrea J Darzi; Allen B Repp; Frederick A Spencer; Rami Z Morsi; Rana Charide; Itziar Etxeandia-Ikobaltzeta; Kenneth A Bauer; Allison E Burnett; Mary Cushman; Francesco Dentali; Susan R Kahn; Suely M Rezende; Neil A Zakai; Arnav Agarwal; Samer G Karam; Tamara Lotfi; Wojtek Wiercioch; Reem Waziry; Alfonso Iorio; Elie A Akl; Holger J Schünemann Journal: Blood Adv Date: 2020-10-13
Authors: Andrea J Darzi; Samer G Karam; Rana Charide; Itziar Etxeandia-Ikobaltzeta; Mary Cushman; Michael K Gould; Lawrence Mbuagbaw; Frederick A Spencer; Alex C Spyropoulos; Michael B Streiff; Scott Woller; Neil A Zakai; Federico Germini; Marta Rigoni; Arnav Agarwal; Rami Z Morsi; Alfonso Iorio; Elie A Akl; Holger J Schünemann Journal: Blood Date: 2020-05-14 Impact factor: 22.113